BioSight
Companies
MOLECULAR PARTNERS AG logo

MOLN

NASDAQSchlieren-Zurich, V8
MOLECULAR PARTNERS AG

Molecular Partners develops drugs using a proprietary technology platform called DARPin (Designed Ankyrin Repeat Proteins) to create targeted protein therapeutics. The company is in clinical-stage development, advancing candidates across multiple therapeutic areas. Molecular Partners is a Swiss-based biotech firm with registered trademarks for its technology platform in major markets including the U.S., EU, and Japan.

Price history not yet available for MOLN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar